Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer

Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Rare Cancers Ther (2013) 1:3–19 DOI 10.1007/s40487-013-0002-8 REVIEW Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Mohamed E. Salem Sherif M. El-Refai To view enhanced content go to www.rarecancers-open.com Received: July 23, 2013 / Published online: October 16, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Methods: A search of PubMed and MEDLINE ABSTRACT from January 2000 to August 2013 was Background: Vascular endothelial growth performed using the following terms (or factor (VEGF) and related pathway elements combination of terms): VEGF, colorectal are critically important in the pathogenesis, cancer, mCRC, aflibercept, ziv-aflibercept. growth, and development of solid tumors. Studies were limited to those published in Inhibiting the VEGF signaling pathway is English. being investigated as a therapeutic strategy for Results: Phase 1 and 2 clinical trials of cancer, either by blockade of VEGF ligand aflibercept in advanced non-hematological binding or inhibition of the VEGF receptor. cancer showed acceptable safety and provided Aflibercept is a VEGF inhibitor that has been justification for further investigation. Four approved by the US Food and Drug phase 3 clinical trials were conducted to Administration for the treatment of macular evaluate aflibercept for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer

Salem, Mohamed; El-Refai, Sherif
Oncology and Therapy , Volume 1 (2) – Oct 16, 2013
Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/efficacy-and-safety-of-aflibercept-and-its-role-in-the-treatment-of-Fe97Y91J4o
Publisher
Springer Journals
Copyright
Copyright © 2013 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-013-0002-8
Publisher site
See Article on Publisher Site

Abstract

Rare Cancers Ther (2013) 1:3–19 DOI 10.1007/s40487-013-0002-8 REVIEW Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Mohamed E. Salem Sherif M. El-Refai To view enhanced content go to www.rarecancers-open.com Received: July 23, 2013 / Published online: October 16, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Methods: A search of PubMed and MEDLINE ABSTRACT from January 2000 to August 2013 was Background: Vascular endothelial growth performed using the following terms (or factor (VEGF) and related pathway elements combination of terms): VEGF, colorectal are critically important in the pathogenesis, cancer, mCRC, aflibercept, ziv-aflibercept. growth, and development of solid tumors. Studies were limited to those published in Inhibiting the VEGF signaling pathway is English. being investigated as a therapeutic strategy for Results: Phase 1 and 2 clinical trials of cancer, either by blockade of VEGF ligand aflibercept in advanced non-hematological binding or inhibition of the VEGF receptor. cancer showed acceptable safety and provided Aflibercept is a VEGF inhibitor that has been justification for further investigation. Four approved by the US Food and Drug phase 3 clinical trials were conducted to Administration for the treatment of macular evaluate aflibercept for

Journal

Oncology and Therapy – Springer Journals

Published: Oct 16, 2013

References

  • Angiogenesis inhibitors: current strategies and future prospects
    Cook, KM; Figg, WD
  • Molecular basis of angiogenesis and cancer
    Tonini, T; Rossi, F; Claudio, PP
  • Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Hicklin, DJ; Ellis, LM
  • Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells
    Galiano, RD; Tepper, OM; Pelo, CR
  • Mechanisms of normal and tumor-derived angiogenesis
    Papetti, M; Herman, IM
  • Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
    Takahashi, Y; Kitadai, Y; Bucana, CD; Cleary, KR; Ellis, LM
  • Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer
    Takahashi, Y; Tucker, SL; Kitadai, Y
  • Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
    Cascinu, S; Staccioli, MP; Gasparini, G
  • Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial
    Ramlau, R; Gorbunova, V; Ciuleanu, TE
  • Anti-PLGF inhibits growth of VEGF®-inhibitor-resistant tumors without affecting healthy vessels
    Fischer, C; Jonckx, B; Mazzone, M
  • VEGF-Trap: a VEGF blocker with potent antitumor effects
    Holash, J; Davis, S; Papadopoulos, N
  • Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
    Huang, J; Frischer, JS; Serur, A
  • Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model
    Byrne, AT; Ross, L; Holash, J
  • Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
    Baffert, F; Le, T; Sennino, B
  • VEGF trap abolishes shear stress- and overload-dependent angiogenesis in skeletal muscle
    Williams, JL; Cartland, D; Rudge, JS; Egginton, S
  • A preclinical and clinical review of aflibercept for the management of cancer
    Gaya, A; Tse, V
  • Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
    Le, XF; Mao, W; Lu, C
  • Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
    Hu, L; Hofmann, J; Holash, J
  • VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma
    Wachsberger, PR; Burd, R; Cardi, C
  • Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumors
    Freyer, G; Isambert, N; You, B
  • Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors
    Isambert, N; Freyer, G; Zanetta, S
  • A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results [abstract]
    Limentani, SA; Just, R; Purdham, A
  • A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results [abstract]
    Patnaik, A; Pipas, M; Rosen, L
  • Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumors
    Cutsem, E; Khayat, D; Verslyp, C
  • A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma [abstract]
    Kuhnowski, F; Thieblemont, C; Jardin, F
  • Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    Tew, WP; Gordon, M; Murren, J
  • Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
    Lockhart, AC; Rothenberg, ML; Dupont, J
  • A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    Diaz-Padilla, I; Siu, LL; San Pedro-Salcedo, M
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer, EA; Therasse, P; Bogaerts, J
  • Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA) [abstract]
    Massarelli, E; Miller, VA; Leighl, NB
  • VEGF-trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study [abstract]
    Tew, WP; Colombo, N; Ray-Coquard, I
  • A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
    Colombo, N; Mangili, G; Mammoliti, S
  • Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer
    Tang, P; Cohen, SJ; Kollmannsberger, C
  • Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin [abstract]
    Tarhini, AA; Christensen, S; Frankel, P
  • A phase II study single agent of aflibercept (VEGF trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia
    Mackay, HJ; Buckanovich, RJ; Hirte, H
  • A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma [abstract]
    Sherman, EJ; Ho, AL; Haque, S
  • Phase II study of aflibercept (VEGF-trap) in patients with recurrent or metastatic urothelial cancer, a California cancer consortium trial
    Twardowski, P; Stadler, WM; Frankel, P
  • Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM): abstract O-0024
    Pericay, CFG; Saunders, M; Thomas, A
  • Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    Cutsem, E; Tabernero, J; Lakomy, R
  • Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
    Tannock, IF; Fizazi, K; Ivanov, S
  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial
    Bennouna, J; Sastre, J; Arnold, D
  • Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF trap) [abstract]
    Piao, Y; Heymach, JV; Bekele, B
  • Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    Groot, JF; Piao, Y; Tran, H
  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Karapetis, CS; Khambata-Ford, S; Jonker, DJ